Clinical Trial Finder

Key

Inclusion Criteria:

1. 18 years and older. 2. Confirmed diagnosis of cystic fibrosis (CF) and CF lung disease including: 1. Sweat chloride ≥ 60 mmol/L. 2. Mutation Status.

• - Bi-allelic mutations in the CFTR gene, or.

• - Single mutation in the CFTR gene and clinical manifestations of CF lung disease.

3. Ineligible for CFTR modulator therapy, or previously received modulator therapy but discontinued due to adverse effects. 3. Forced expiratory volume in 1 second (FEV1) ≥50% and ≤100% of predicted (per Global Lung Function Initiative) at Screening. 4. Resting oxygen saturation ≥ 92% on room air at Screening. Key

Exclusion Criteria:

1. Any prior gene therapy for any indication (Exception: mRNA-based therapies are not exclusionary) 2. Active Mycobacterium abscessus infection requiring ongoing treatment at Screening. 3. Active allergic bronchopulmonary aspergillosis requiring management with systemic corticosteroids or antifungal therapy. 4. Two or more pulmonary exacerbations requiring treatment with intravenous (IV) antibiotics within 6 months prior to Screening. 5. Contraindication to systemic corticosteroid therapy. 6. Requires chronic use of systemic corticosteroids or immunosuppressants to treat another condition. 7. If no known diagnosis of cystic fibrosis related diabetes (CFRD), Type I, or Type II diabetes: Hemoglobin A1C ≥6.5% at Screening. 8. If known diagnosis of CFRD, Type I or Type II diabetes: Hemoglobin A1C >7.5% at Screening. 9. Recent history of symptomatic hyperglycemia or unstable blood glucose levels as per Investigator's assessment. 10. Other conditions that, in the Investigator's opinion, may interfere with management of corticosteroid-related hyperglycemia. 11. Body Mass Index (BMI) <16. 12. Laboratory abnormalities at screening:

• - ALT, AST or GGT ≥ 3 × the upper limit of normal (ULN) - Total bilirubin ≥ 2 × ULN.

• - Hemoglobin < 10 g/dL.

13. Requirement for continuous or night-time oxygen supplementation. 14. Known CF liver disease with evidence of cirrhosis. 15. History of thrombosis (excluding catheter-related thrombosis) or conditions associated with increased risk of thrombosis

This Phase 1/2 trial will evaluate the safety, tolerability, and preliminary efficacy of 4 dose levels of 4D-710, an investigational gene therapy, in adults with cystic fibrosis lung disease who are ineligible or unable to tolerate CFTR modulator therapy.

Arms

Experimental: 4D-710 Dose Exploration Cohort 1

Single inhalational administration of 4D-710 Dose 1

Experimental: 4D-710 Dose Exploration Cohort 2

Single inhalational administration of 4D-710 Dose 2

Experimental: 4D-710 Dose Exploration Cohort 3

Single inhalational administration of 4D-710 Dose 3

Experimental: 4D-710 Dose Exploration Cohort 4

Single inhalational administration of 4D-710 Dose 4

Experimental: 4D-710 Dose Expansion Cohort

Single inhalational administration of 4D-710 at the selected dose

Interventions

Biological: - 4D-710

4D-710 is an adeno-associated virus (AAV) gene therapy comprised of an AAV capsid variant (4D-A101) carrying a transgene cassette encoding human cystic fibrosis transmembrane conductance regulator with a deletion in the regulatory domain (CFTRΔR).